Filipe Amado Profile picture
Mar 21 4 tweets 2 min read
Important results presented during the opening ceremony #ISICEM23!
@ISICEM
✅ Hydrocortisone reduces mortality in sCAP (bit.ly/3ZbqHUc)
✅ Ravulizumab did not improve survival or other key outcomes in patients hospitalised with severe COVID-19 (bit.ly/3JVDdTm)
✅ no benefit in PCC administration in trauma patients at risk of massive transfusion (bit.ly/3Jvu7va)
✅ therapeutic-dose heparin: beneficial in hospitalized C19 patients less severely ill at presentation or lower body mass index (bit.ly/3Jq1uiE)

(2/3)
✅ Low-calorie low-protein feeding (acute phase of critical illness): Faster recovery, fewer complications (bit.ly/3TtMg0X)
✅ In the absence of early parenteral nutrition, tight glucose control did not reduce duration of ICU dependency.
(3/3)
@giovannilandoni we have some links here!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Filipe Amado

Filipe Amado Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(